Medpace Holdings, Inc. (MEDP)

Medpace Holdings, Inc. is a well-established contract research organization (CRO) that provides comprehensive development services for the biotechnology, pharmaceutical, and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace offers a suite of services that span the entire drug development process, including phase I-IV clinical trial management, regulatory consulting, and other research services. The company is known for its scientifically-driven approach and is committed to delivering high-quality and timely results to its clients. Medpace serves clients globally, with operations extending across North America, Europe, Asia, and other regions, allowing it to manage complex multinational trials efficiently. Under the leadership of President and CEO Dr. August J. Troendle, who founded the company, Medpace has grown significantly while maintaining a strong emphasis on integrating therapeutic and operational expertise. As of the latest available data, the company reported revenue reflecting its robust growth trajectory, but for the latest financial specifics, one should refer to the company's most recent fiscal reports. Medpace is publicly traded on the NASDAQ under the ticker symbol "MEDP," attracting investors interested in the expansive field of medical research and development. The company's strong focus on scientific integrity and client service has established it as a trusted partner in the CRO industry.